DK2068918T3 - Vaccinesammensætning omfattende syntetisk adjuvant - Google Patents

Vaccinesammensætning omfattende syntetisk adjuvant

Info

Publication number
DK2068918T3
DK2068918T3 DK07875082.5T DK07875082T DK2068918T3 DK 2068918 T3 DK2068918 T3 DK 2068918T3 DK 07875082 T DK07875082 T DK 07875082T DK 2068918 T3 DK2068918 T3 DK 2068918T3
Authority
DK
Denmark
Prior art keywords
adjuvant
gla
vaccine composition
lot
synthetic
Prior art date
Application number
DK07875082.5T
Other languages
English (en)
Other versions
DK2068918T4 (da
Inventor
Steven G Reed
Darrick Carter
Original Assignee
Infectious Disease Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39776582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2068918(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Infectious Disease Res Inst filed Critical Infectious Disease Res Inst
Application granted granted Critical
Publication of DK2068918T3 publication Critical patent/DK2068918T3/da
Publication of DK2068918T4 publication Critical patent/DK2068918T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK07875082.5T 2006-09-26 2007-09-26 Vaccinesammensætning omfattende syntetisk adjuvant DK2068918T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84740406P 2006-09-26 2006-09-26
PCT/US2007/021017 WO2008153541A1 (en) 2006-09-26 2007-09-26 Vaccine composition containing synthetic adjuvant

Publications (2)

Publication Number Publication Date
DK2068918T3 true DK2068918T3 (da) 2012-07-30
DK2068918T4 DK2068918T4 (da) 2024-09-02

Family

ID=39776582

Family Applications (4)

Application Number Title Priority Date Filing Date
DK12153267.5T DK2468300T3 (da) 2006-09-26 2007-09-26 Vaccinesammensætning indeholdende syntetisk adjuvant
DK12153256.8T DK2486938T3 (da) 2006-09-26 2007-09-26 Vaccinesammensætning indeholdende syntetisk adjuvans
DK07875082.5T DK2068918T4 (da) 2006-09-26 2007-09-26 Vaccinesammensætning omfattende syntetisk adjuvant
DK12153249.3T DK2484375T3 (da) 2006-09-26 2007-09-26 Vaccinesammensætning omfattende syntetisk adjuvans

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK12153267.5T DK2468300T3 (da) 2006-09-26 2007-09-26 Vaccinesammensætning indeholdende syntetisk adjuvant
DK12153256.8T DK2486938T3 (da) 2006-09-26 2007-09-26 Vaccinesammensætning indeholdende syntetisk adjuvans

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12153249.3T DK2484375T3 (da) 2006-09-26 2007-09-26 Vaccinesammensætning omfattende syntetisk adjuvans

Country Status (20)

Country Link
US (10) US8273361B2 (da)
EP (6) EP2068918B2 (da)
JP (6) JP5443164B2 (da)
KR (1) KR101378872B1 (da)
CN (2) CN103705919B (da)
AT (1) ATE555808T1 (da)
AU (1) AU2007354917B2 (da)
BR (1) BRPI0716959A2 (da)
CA (1) CA2662921C (da)
CY (4) CY1112943T1 (da)
DK (4) DK2468300T3 (da)
ES (5) ES2673046T3 (da)
FI (1) FI2068918T4 (da)
HU (3) HUE037808T2 (da)
LT (3) LT2486938T (da)
PL (4) PL2068918T5 (da)
PT (4) PT2468300T (da)
SI (4) SI2068918T2 (da)
TR (2) TR201807756T4 (da)
WO (1) WO2008153541A1 (da)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CN1918293A (zh) * 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) * 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20110245323A1 (en) * 2006-10-16 2011-10-06 Yale University RIG-Like Helicase Innate Immunity Inhibits VEGF-Induced Tissue Responses
ES2621211T3 (es) 2007-04-04 2017-07-03 Infectious Disease Research Institute Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos
SI2280720T1 (sl) 2008-03-27 2019-06-28 Purdue Research Foundation Sintetični peptidoglikani,ki vežejo kolagen, priprava in postopki uporabe
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US8425919B2 (en) * 2008-05-21 2013-04-23 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
RS51999B (sr) * 2008-08-28 2012-04-30 Novartis Ag Dobijanje skvalena iz hiperprodukcijskih kvasaca
WO2010033812A1 (en) * 2008-09-18 2010-03-25 Variation Biotechnologies, Inc. Compositions and methods for treating hepatitis a.
HUE027823T2 (hu) 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
WO2010091265A1 (en) * 2009-02-05 2010-08-12 Yale University Compounds and methods for treating viral encephalitis
CN102481312B (zh) * 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
US20110014228A1 (en) * 2009-06-15 2011-01-20 New York University Il23 modified viral vector for recombinant vaccines and tumor treatment
AU2010270722B2 (en) * 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
ES2455544T5 (es) 2009-07-24 2017-08-16 Immune Design Corp Vectores de lentivirus pseudotipificados con una glucoproteína de envoltura de virus sindbis
EP2461679B1 (en) 2009-07-28 2019-02-13 GE Healthcare Bio-Sciences Corp. Vaccine stabilizer
US9259476B2 (en) 2009-07-31 2016-02-16 Wayne State University Monophosphorylated lipid A derivatives
CN102596220A (zh) 2009-07-31 2012-07-18 韦恩州立大学 单磷酸化的脂质a衍生物
ES2536429T3 (es) * 2010-01-24 2015-05-25 Novartis Ag Micropartículas de polímero biodegradables irradiadas
US20110305748A1 (en) * 2010-03-11 2011-12-15 Immune Design, Corp. Vaccines for Pandemic Influenza
BR112012027745A2 (pt) 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia
CN101850117B (zh) * 2010-06-03 2012-05-30 国家兽用生物制品工程技术研究中心 一种复方免疫佐剂及疫苗
WO2011163492A1 (en) * 2010-06-23 2011-12-29 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for use in vascular intervention
MX342138B (es) * 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
US20120114688A1 (en) 2010-11-08 2012-05-10 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20120263754A1 (en) * 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
WO2012141984A1 (en) * 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
KR101376675B1 (ko) * 2011-04-19 2014-03-20 광주과학기술원 이미징 및 운반 이중기능 나노입자－기반 백신 전달체
US20120288515A1 (en) * 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
WO2012156391A1 (en) * 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
HRP20170482T1 (hr) 2011-05-24 2017-05-19 Symic Ip, Llc Sintetski peptidoglikani koji vežu hijaluronsku kiselinu, dobivanje, i postupci uporabe
ES2936312T3 (es) * 2011-08-31 2023-03-16 Perosphere Tech Inc Métodos para la desensibilización eficaz y rápida de pacientes alérgicos
WO2013038185A1 (en) 2011-09-12 2013-03-21 Jonathan Norden Weber Methods and compositions for raising an immune response to hiv
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
PL2811981T3 (pl) * 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
EP2822599A4 (en) * 2012-03-05 2015-12-23 Univ Duke VACCINE FORMULATION
PT2831095T (pt) 2012-03-30 2019-01-30 Immune Design Corp Partículas de vectores lentivirais com melhor eficácia de transdução de células que expressam dc-sign
KR102136433B1 (ko) * 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
MX385774B (es) 2012-08-03 2025-03-18 Infectious Disease Res Inst Composiciones para usarse en el tratamiento de una infección activa por mycobacterium tuberculosis.
CN103768604B (zh) * 2012-10-24 2016-03-30 北京圣沃德生物科技有限公司 治疗性肿瘤疫苗
ES2819234T3 (es) * 2013-02-25 2021-04-15 Particle Sciences Inc Formulaciones de partículas para la administración de agonistas de TLR y antígenos
US9200039B2 (en) 2013-03-15 2015-12-01 Symic Ip, Llc Extracellular matrix-binding synthetic peptidoglycans
EP2978447B1 (en) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EP2986303B1 (en) * 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
EP3041478A4 (en) * 2013-09-05 2017-04-26 Immune Design Corp. Vaccine compositions for drug addiction
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
NZ721015A (en) 2014-01-09 2017-09-29 Valneva Austria Gmbh Mutant fragments of ospa and methods and uses relating thereto
CA2935722A1 (en) * 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
EP3134104B1 (en) 2014-04-25 2018-12-26 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3169352A1 (en) 2014-07-15 2017-05-24 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
ES2856834T3 (es) * 2014-08-04 2021-09-28 Oncotherapy Science Inc Péptido derivado de URLC10 y vacuna que contiene el mismo
AU2015310518A1 (en) * 2014-09-02 2017-03-09 Cadila Healthcare Limited Synergistic compositions of immunostimulating reconstituted influenza virosomes with immunopotentiators and vaccines containing them
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
EP3069729A1 (en) 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3270962A4 (en) * 2015-03-17 2018-08-22 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
TW201709926A (zh) * 2015-04-23 2017-03-16 賽諾菲公司 用於舌下投藥之吡喃葡萄糖基脂ａ及過敏原調配物
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
WO2017044661A1 (en) 2015-09-09 2017-03-16 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
CN108350037A (zh) 2015-11-09 2018-07-31 免疫设计股份有限公司 包含表达il-12的慢病毒载体的组合物及其使用方法
KR20180074699A (ko) 2015-11-09 2018-07-03 이뮨 디자인 코포레이션 이종 핵산을 발현하는 rna 레플리콘의 발현 및 투여를 위한 레트로바이러스 벡터
PL3417049T3 (pl) 2016-02-15 2024-02-19 Hipra Scientific, S.L.U. Ekstrakt ze streptococcus uberis jako środek immunogenny
HK1258353A1 (zh) 2016-02-23 2019-11-08 Immune Design Corp. 多基因组逆转录病毒载体制剂及用於制备及使用该制剂的方法和系统
CN105749275A (zh) * 2016-03-30 2016-07-13 山东农业大学 一种核酸缓释佐剂及其制备和使用方法
US11266602B2 (en) 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
KR20190009308A (ko) 2016-05-21 2019-01-28 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 2차 결핵 및 비결핵성 마이코박테리아 감염을 치료하기 위한 조성물 및 방법
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals S.A. métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
AU2017389221B2 (en) * 2016-12-26 2020-10-08 Access To Advanced Health Institute Herpes zoster vaccine composition
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
KR101996538B1 (ko) * 2017-02-13 2019-07-04 단디바이오사이언스 주식회사 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
EP3615061A1 (en) 2017-04-28 2020-03-04 GlaxoSmithKline Biologicals S.A. Vaccination
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
JP2020524143A (ja) 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用
WO2019010484A2 (en) 2017-07-07 2019-01-10 Symic Ip, Llc SYNTHETIC BIOCONJUGATES
CN110123159A (zh) * 2017-08-09 2019-08-16 沙克忍者运营有限责任公司 烹饪系统
CA3078223A1 (en) * 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
ES2985591T3 (es) 2018-02-12 2024-11-06 Inimmune Corp Ligandos de receptores tipo Toll
ES3038006T3 (en) 2018-07-31 2025-10-08 Glaxosmithkline Biologicals Sa Antigen purification method
US12397052B2 (en) * 2018-08-20 2025-08-26 Institute Of Process Engineering, Chinese Academy Of Sciences Microcapsule-based vaccine
CN112770771A (zh) * 2018-09-17 2021-05-07 丘拉提斯股份有限公司 包含干扰素基因刺激蛋白激动剂的免疫佐剂及疫苗组合物
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
CN109701011B (zh) * 2019-02-26 2022-04-05 苏文全 疫苗复合佐剂系统及其在抗原中的应用
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
WO2020247851A1 (en) * 2019-06-05 2020-12-10 Global Health Solutions Llc Transdermal vaccine delivery
US11911463B2 (en) 2019-07-16 2024-02-27 Michael J. Dochniak Topical hyper-allergenic composition and method of treating using the same
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021048081A1 (en) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
MX2022004061A (es) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Peptidos de estafilococo y metodos de uso.
RU2724896C1 (ru) * 2019-11-14 2020-06-26 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Полиантигенная вакцина для профилактики и вспомогательного лечения туберкулеза
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
KR20210117832A (ko) * 2020-03-20 2021-09-29 강원대학교산학협력단 Gla-se를 포함하는 수족구병 백신 조성물
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
US11647861B2 (en) 2020-03-30 2023-05-16 Sharkninja Operating Llc Cooking device and components thereof
CN115698044A (zh) 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物
US20230277657A1 (en) 2020-05-05 2023-09-07 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
AU2021321944A1 (en) 2020-08-07 2023-04-06 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
EP4199961A4 (en) * 2020-08-20 2024-03-13 The Board of Regents of the University of Texas System COMBINATION IMMUNOTHERAPY METHOD FOR TREATING CANCER
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
MX2023006769A (es) 2020-12-09 2023-08-18 Glaxosmithkline Biologicals Sa Modificacion de saponinas.
CN117120087A (zh) 2020-12-23 2023-11-24 高级健康研究所 茄尼醇疫苗助剂及其制备方法
US20240102069A1 (en) 2020-12-24 2024-03-28 Plant Bioscience Limited Methods and compositions
WO2022226035A1 (en) * 2021-04-21 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Toll-like receptor agonist-nanoparticle vaccine adjuvant
WO2022233629A1 (en) 2021-05-06 2022-11-10 Hipra Scientific, S.L.U. Sars-cov-2 subunit vaccine
BR112023023098A2 (pt) 2021-05-06 2024-01-30 Hipra Scient S L U Vacina de subunidade de sars-cov-2
CN113416255A (zh) * 2021-06-02 2021-09-21 广西大学 一种抗大片形吸虫Cat L1单克隆抗体及其制备方法与应用
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
EP4405372A4 (en) 2021-09-22 2026-01-14 Hdt Bio Corp SARS-CoV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
KR20240096468A (ko) 2021-09-22 2024-06-26 에이치디티 바이오 코포레이션 감염병에 대한 rna 백신
WO2023180677A1 (en) 2022-03-25 2023-09-28 Plant Bioscience Limited Biosynthesis
EP4540401A1 (en) 2022-06-15 2025-04-23 GlaxoSmithKline Biologicals S.A. Enzymatic modification of saponins
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
KR102901149B1 (ko) * 2022-09-05 2025-12-17 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법
EP4583841A1 (en) 2022-09-09 2025-07-16 Access to Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
EP4608438A1 (en) * 2022-10-24 2025-09-03 Virginia Commonwealth University Chimeric recombinant proteins and recombinant protein panels for the diagnosis of lyme disease in animals and humans
WO2024174011A1 (pt) 2023-02-24 2024-08-29 Rossi Bergmann Bartira Lipossoma, método de preparo de um lipossoma, composição intranasal compreendendo lipossoma, método de preparo de composição intranasal, kit e uso da composição

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001427A (en) 1911-05-13 1911-08-22 Walter S Morton Concrete dam.
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4029762A (en) 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4420558A (en) 1981-02-12 1983-12-13 Janssen Pharmaceutica N.V. Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
JPS591527A (ja) 1982-06-25 1984-01-06 Mitsubishi Monsanto Chem Co ポリエステルの製造方法
US4420461A (en) 1982-05-26 1983-12-13 Ortho Diagnostic Systems Inc. Agglutination-inhibition test kit for detecting immune complexes
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4743540A (en) 1983-09-27 1988-05-10 Memorial Sloan-Kettering Cancer Center Method for diagnosis of subclassifications of common varied immunodeficiency disease group
US4614722A (en) 1983-11-01 1986-09-30 Pasula Mark J Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
US5147785A (en) 1983-11-01 1992-09-15 Amtl Corporation Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4629722A (en) 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US4844894A (en) 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4659659A (en) 1985-01-22 1987-04-21 Monsanto Company Diagnostic method for diseases having an arthritic component
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4746742A (en) * 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
US6544728B1 (en) 1986-01-22 2003-04-08 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2 (HIV-2), proteins of HIV-2, and vaccinating agents for HIV-2
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US5310651A (en) 1986-01-22 1994-05-10 Institut Pasteur DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2
US6054565A (en) 1986-03-03 2000-04-25 Institut Pasteur Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
US5169763A (en) 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JPH0755906B2 (ja) 1986-07-01 1995-06-14 第一製薬株式会社 ジサツカライド誘導体含有鎮痛剤
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US5565209A (en) 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0324455A3 (en) 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3826572A1 (de) 1988-08-04 1990-02-08 Hoechst Ag Verfahren zur herstellung von hochreinem 5,5'-(2,2,2-trifluor-1-(trifluormethyl) -ethyliden) bis-1,3-isobenzofurandion, verwendung des verfahrensproduktes zur herstellung von polyimiden sowie deren verwendung in der mikroelektronik
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5231168A (en) 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
RU2121481C1 (ru) 1988-12-16 1998-11-10 Де Стат Дер Недерланден Вертегенвордигд Дор де Министр Ван Велзейн, Волксгезондхейд эн Кюлтюр Модифицированный пневмолизин, рекомбинантная плазмида, способ получения модифицированного пневмолизина, вакцина
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
US4886034A (en) 1989-03-30 1989-12-12 Gas Research Institute Internal combustion engine control system
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5158939A (en) 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US4981684A (en) 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US6120769A (en) 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5124141A (en) 1990-06-14 1992-06-23 Flow Incorporated Method for diagnosing malaria
US5162990A (en) 1990-06-15 1992-11-10 The United States Of America As Represented By The United States Navy System and method for quantifying macrophage phagocytosis by computer image analysis
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DE122007000016I1 (de) 1991-07-19 2007-05-24 Univ Queensland Impfstoffe gegen Papillomavirus
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
WO1993001831A1 (en) 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Induction of cytotoxic t-lymphocyte responses
DE69207603T2 (de) 1991-08-16 1996-09-12 Vical Inc Zusammensetzung und verfahren zur behandlung von zystischer fibrose
AU660325B2 (en) 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
ATE177755T1 (de) 1991-11-16 1999-04-15 Smithkline Beecham Biolog Hybrides protein zwischen cs aus plasmodium und hbsag
US6057427A (en) 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
US5286718A (en) 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
JPH05328975A (ja) 1992-06-02 1993-12-14 Takara Shuzo Co Ltd Ｅ１ａ−ｆ遺伝子
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
DE122007000099I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5411865A (en) 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
DE69434383T2 (de) 1993-03-09 2005-11-24 The University Of Rochester Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5532133A (en) 1993-06-02 1996-07-02 New York University Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays
JP3286030B2 (ja) 1993-08-10 2002-05-27 株式会社東芝 保全管理装置および保全管理ガイド装置
US6106824A (en) 1993-08-13 2000-08-22 The Rockefeller University Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
DE69433695T2 (de) 1993-11-02 2004-08-12 Matsushita Electric Industrial Co., Ltd., Kadoma Halbleiterbauelement mit Aggregat von Mikro-Nadeln aus Halbleitermaterial
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
PT729473E (pt) 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US7037712B2 (en) 1994-07-26 2006-05-02 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
SE9403137D0 (sv) 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
WO1996011272A2 (de) 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
JP3844501B2 (ja) 1995-02-08 2006-11-15 タカラバイオ株式会社 癌の制御
US5955087A (en) 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6417172B1 (en) 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5631245A (en) * 1995-06-06 1997-05-20 Biodynamics Pharmaceuticals, Inc. Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
US6309847B1 (en) 1995-07-05 2001-10-30 Yeda Research And Development Co. Ltd. Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US5952309A (en) 1995-09-29 1999-09-14 Eisai Company, Ltd. Method for treating alcoholic liver disease
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5846758A (en) 1995-11-30 1998-12-08 His Excellency Ghassan I. Shaker Method for diagnosing autoimmune diseases
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
SE9600648D0 (sv) 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
DK0909562T3 (da) 1996-07-03 2005-08-22 Eisai Co Ltd Injektionspræparat indeholdende en lipid A analog og fremgangsmåde til fremstilling deraf
ATE229073T1 (de) 1996-09-06 2002-12-15 Univ California Protein e25a, methoden zu dessen herstellung und anwendung
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
JPH10131046A (ja) 1996-10-29 1998-05-19 Nikka Chem Co Ltd 繊維の耐久性ｐＨ緩衝加工方法
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
DE19654221B4 (de) 1996-12-23 2005-11-24 Telefonaktiebolaget Lm Ericsson (Publ) Leitungsanschlußschaltkreis
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
WO1998037418A2 (en) 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
AU7983198A (en) * 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
JP2001510031A (ja) 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6645495B1 (en) 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR100735651B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
US7012134B2 (en) 1998-01-26 2006-03-14 Human Genome Sciences, Inc. Dendritic enriched secreted lymphocyte activation molecule
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
PT1053325E (pt) 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
WO1999040938A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Vaccines comprising interleukin-12 and herpes simplex viral antigen
EP0936629B1 (de) 1998-02-12 2006-09-13 Infineon Technologies AG EEPROM und Verfahren zur Ansteuerung eines EEPROM
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
WO1999045957A2 (en) 1998-03-09 1999-09-16 Smithkline Beecham Biologicals S.A. Combined vaccine compositions
WO1999051748A2 (en) 1998-04-07 1999-10-14 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
JP2002511266A (ja) 1998-04-15 2002-04-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 腫瘍関連核酸及びその使用
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
HK1039072A1 (zh) 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
CN100419079C (zh) 1998-07-14 2008-09-17 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
EP1111390A4 (en) 1998-09-01 2007-11-14 Eisai R&D Man Co Ltd METHOD FOR EVALUATING INJECTIONS CONTAINING LIPID A ANALOGS
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
AU5980899A (en) 1998-09-25 2000-04-17 Smithkline Beecham Biologicals (Sa) Novel compounds
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
WO2000042994A2 (en) 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
US6919210B1 (en) 1999-04-07 2005-07-19 Hiroshi Okamoto Method for identifying autoimmune disease, method for detecting anti-Reg protein autoantibody and diagnostics for autoimmune disease
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
US6685699B1 (en) 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
AU6884200A (en) 1999-08-26 2001-03-19 Biovitrum Ab Novel response element
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7084256B2 (en) 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
JP4162813B2 (ja) 1999-10-28 2008-10-08 久光製薬株式会社 イオントフォレーシス装置
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
ES2370262T3 (es) 1999-11-15 2011-12-14 Oncothyreon Inc. Análogos del lípido a sintéticos y sus utilizaciones.
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6587792B1 (en) 2000-01-11 2003-07-01 Richard A. Thomas Nuclear packing efficiency
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
WO2001055362A2 (en) 2000-01-31 2001-08-02 The Governement Of The United States Of America, As Represented By The Secretary, Departement Of Health & Human Services, The National Institutes Of Health Hybrid adeno-retroviral vector for the transfection of cells
EP1122542A1 (en) 2000-02-01 2001-08-08 Anda Biologicals S.A. Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
EP2000144A1 (en) 2000-05-19 2008-12-10 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds
AU2001265219A1 (en) 2000-05-31 2001-12-11 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
EP1341546B1 (en) 2000-10-06 2011-09-21 The Symbio Herborn Group GmbH u.Co Kyberdrug as autovaccines with immune-regulating effects
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
JP2004511527A (ja) 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
CA2462946C (en) 2001-01-26 2014-04-29 Jeffrey A. Lyon Recombinant p. falciparum merozoite protein-142 vaccine
US6893820B1 (en) 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
GB0105360D0 (en) 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US7029685B2 (en) 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
AU2002306896B2 (en) 2001-03-26 2007-04-26 Walter Reed Army Institute Of Research Plasmodium falciparum AMA-1 protein and uses thereof
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
AU2002339865A1 (en) 2001-09-05 2003-03-18 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US7820627B2 (en) 2002-05-09 2010-10-26 Oncothyreon Inc. Lipid A and other carbohydrate ligand analogs
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
TW200416046A (en) * 2002-12-23 2004-09-01 Alcon Inc Contact lens care compositions containing chitin derivatives
US20050123550A1 (en) 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
FR2857875A1 (fr) 2003-07-25 2005-01-28 Univ Reims Champagne Ardenne Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers
US20050244419A1 (en) 2003-07-25 2005-11-03 Pierre-Francois Tosi Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
FR2862062B1 (fr) 2003-11-06 2005-12-23 Oreal Lipide a et composition topique, notamment cosmetique, le comprenant
US20060135906A1 (en) * 2004-11-16 2006-06-22 Akihiko Matsumura Iontophoretic device and method for administering immune response-enhancing agents and compositions
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
US9241988B2 (en) 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
JP5328975B2 (ja) 2012-12-19 2013-10-30 ルネサスエレクトロニクス株式会社 Ｒｆパワーモジュール

Also Published As

Publication number Publication date
JP5443164B2 (ja) 2014-03-19
JP2014012698A (ja) 2014-01-23
CN103705919B (zh) 2016-09-28
CY1119822T1 (el) 2018-06-27
US20150335736A1 (en) 2015-11-26
US20210069324A1 (en) 2021-03-11
DK2068918T4 (da) 2024-09-02
ES2387327T3 (es) 2012-09-20
SI2484375T1 (en) 2018-08-31
CN103705919A (zh) 2014-04-09
DK2468300T3 (da) 2018-01-29
DK2484375T3 (da) 2018-07-16
ES2657392T3 (es) 2018-03-05
KR20090079209A (ko) 2009-07-21
LT2468300T (lt) 2018-02-12
US20180221470A1 (en) 2018-08-09
PT2486938T (pt) 2018-06-12
DK2486938T3 (da) 2018-06-14
US9987355B2 (en) 2018-06-05
EP3403667A1 (en) 2018-11-21
PL2068918T3 (pl) 2012-10-31
PL2484375T3 (pl) 2018-09-28
EP3403667B1 (en) 2020-07-22
HUE037808T2 (hu) 2018-09-28
CN101516396B (zh) 2013-10-09
PT2068918E (pt) 2012-08-06
SI2068918T1 (sl) 2012-09-28
US20210069323A1 (en) 2021-03-11
LT2484375T (lt) 2018-07-10
CN101516396A (zh) 2009-08-26
PT2468300T (pt) 2018-01-30
PL2468300T3 (pl) 2018-04-30
US8609114B2 (en) 2013-12-17
EP2486938B1 (en) 2018-05-09
EP2068918B1 (en) 2012-05-02
LT2486938T (lt) 2018-06-25
US20140037691A1 (en) 2014-02-06
ES2822058T3 (es) 2021-04-28
SI2486938T1 (sl) 2018-09-28
US9907845B2 (en) 2018-03-06
HK1132934A1 (en) 2010-03-12
EP2068918B2 (en) 2024-07-03
US10792359B2 (en) 2020-10-06
CA2662921A1 (en) 2008-12-18
JP2010504914A (ja) 2010-02-18
PT2484375T (pt) 2018-07-09
US9950063B2 (en) 2018-04-24
AU2007354917B2 (en) 2013-06-06
EP2468300A1 (en) 2012-06-27
JP2018024656A (ja) 2018-02-15
CA2662921C (en) 2018-11-20
US20140341970A1 (en) 2014-11-20
BRPI0716959A2 (pt) 2013-10-29
CY1112943T1 (el) 2016-04-13
US8840908B2 (en) 2014-09-23
JP2017081921A (ja) 2017-05-18
JP6463808B2 (ja) 2019-02-06
FI2068918T4 (fi) 2024-08-16
EP2484375A3 (en) 2012-08-15
PL2068918T5 (pl) 2024-12-02
EP2484375B1 (en) 2018-05-23
ATE555808T1 (de) 2012-05-15
TR201807756T4 (tr) 2018-06-21
CY1120305T1 (el) 2019-07-10
ES2673046T3 (es) 2018-06-19
WO2008153541A1 (en) 2008-12-18
US20080131466A1 (en) 2008-06-05
EP2486938A1 (en) 2012-08-15
US20180236063A1 (en) 2018-08-23
SI2468300T1 (en) 2018-03-30
ES2387327T5 (es) 2024-11-19
US20130058997A1 (en) 2013-03-07
CY1120328T1 (el) 2019-07-10
EP3795173A1 (en) 2021-03-24
EP2484375A2 (en) 2012-08-08
JP2016000738A (ja) 2016-01-07
US20130084307A1 (en) 2013-04-04
JP2019070007A (ja) 2019-05-09
HUE037901T2 (hu) 2018-09-28
HUE036180T2 (hu) 2018-06-28
PL2486938T3 (pl) 2018-08-31
EP2468300B1 (en) 2017-12-20
SI2068918T2 (sl) 2024-10-30
US8273361B2 (en) 2012-09-25
US10765736B2 (en) 2020-09-08
JP5778725B2 (ja) 2015-09-16
TR201809043T4 (tr) 2018-07-23
EP2068918A1 (en) 2009-06-17
JP6190031B2 (ja) 2017-08-30
KR101378872B1 (ko) 2014-04-11
ES2675915T3 (es) 2018-07-13
AU2007354917A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
DK2068918T3 (da) Vaccinesammensætning omfattende syntetisk adjuvant
WO2009143457A3 (en) Vaccine composition containing synthetic adjuvant
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
TW200745158A (en) Compositions that include hemagglutinin, methods of making and methods of use thereof
BRPI0520330B8 (pt) adjuvante a base de ácido polinosínico-policitidílico
BRPI0708344B8 (pt) vetores adenovirais quiméricos e composição imunogênica
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
GB2434367A (en) Improved vaccines
EA200900024A1 (ru) Противогриппозная вакцина
EP2762153A3 (en) Vaccine composition for mucosal administration
PT1951300E (pt) Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
MX362166B (es) Nueva vacuna veterinaria.
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
WO2006114680A8 (en) Vaccine adjuvants
RU2012151576A (ru) Адъювантированные толерогены в качестве вакцины от малярии